metallothionein and Brain-Neoplasms

Metallothioneins (MTs) are intracellular proteins containing the highest amount of thiol groups within the cytoplasm. These thiol groups are able to bind several cytotoxic agents, such as platinum compounds and alkylating agents. Increased levels of MT are one mechanism of resistance to these anticancer drugs, as intracytoplasmic binding of MT prevents the active molecules from reaching their target, the intranuclear DNA of tumor cells. MT synthesis can easily be induced by physiologic heavy metals such as zinc and copper. Pharmacological modulation of MT levels has been used to increase the MT pool in normal tissues and decrease their susceptibility to the toxicity of anticancer drugs. In the case of tumors arising in the brain, where the inducibility of MT synthesis is low, this approach would allow protection of normal tissues without decreasing the antitumor activity of the cytotoxic agents. The interaction of MT with cytotoxic agents is not limited to covalent binding. A correlation between MT synthesis and amplification of oncogenes such as ras has been reported. Furthermore, the cytotoxic drugs are bound by MT after competition with zinc and copper; these metals are cofactors of numerous metalloenzymes, some of which are involved in the metabolism of nucleic acids. Competitive displacement of these metals might modify nucleic acid metabolism and influence cellular proliferation. On the other hand, increased MT levels could provide a zinc cofactor reserve that increases the cell's reparative potential when faced by DNA damage by cytotoxic agents.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Drug Resistance; Humans; Metallothionein; Platinum Compounds

Although metallothionein-3 (MT3), a brain-enriched form of metallothioneins, has been linked to Alzheimer's disease, little is known regarding the role of MT3 in glioma. As MT3 plays a role in autophagy in astrocytes, here, we investigated its role in irradiated glioma cells. Irradiation increased autophagy flux in GL261 glioma cells as evidenced by increased levels of LC3-II but decreased levels of p62 (SQSTM1). Indicating that autophagy plays a cytoprotective role in glioma cell survival following irradiation, measures inhibiting autophagy flux at various steps decreased their clonogenic survival of irradiated GL261 as well as SF295 and U251 glioma cells. Knockdown of MT3 with siRNA in irradiated glioma cells induced arrested autophagy, and decreased cell survival. At the same time, the accumulation of labile zinc in lysosomes was markedly attenuated by MT3 knockdown. Indicating that such zinc accumulation was important in autophagy flux, chelation of zinc with tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN), induced arrested autophagy in and reduced survival of GL261 cells following irradiation. Suggesting a possible mechanism for arrested autophagy, MT3 knockdown and zinc chelation were found to impair lysosomal acidification. Since autophagy flux plays a cytoprotective role in irradiated glioma cells, present results suggest that MT3 and zinc may be regarded as possible therapeutic targets to sensitize glioma cells to ionizing radiation therapy.

Topics: Animals; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chelating Agents; Ethylenediamines; Gene Knockdown Techniques; Glioma; Humans; Lysosomes; Metallothionein; Metallothionein 3; Mice; Nerve Tissue Proteins; Photons; Radiation Tolerance; RNA, Small Interfering; Zinc

Gliomas are heterogeneous, primary brain tumours that originate from glial cells. The main type of gliomas is astrocytomas. There are four grades (I-IV) of astrocytoma malignancy. Astrocytoma grade IV known as glioblastoma multiforme (GBM) is the most common and aggressive type of astrocytic gliomas. Metallothioneins (MT) are low molecular weight, cysteine rich proteins encoded by a family of metallothionein (MT) genes. MT genes play a crucial role in carcinogenesis of diverse malignancies. We proposed MT genes as prognostic markers for malignant astrocytoma. MT1A, MT1E, MT1X, MT2, MT3 gene expression was elevated in grade IV astrocytomas (glioblastomas) as compared to astrocytomas grade I-III. Statistically significant differences were reached for MT1A and MT2 genes (Mann-Whitney test, p < 0.05). High MT1A, MT1X, MT2, MT3 genes expression was associated with shorter patient survival (Log-rank test, p < 0.05). MT1A gene promoter methylation was decreased in glioblastoma (57.6%) while the gene was highly methylated in grade II-III astrocytoma (from 66.7% to 83.3%) and associated with better patient survival (p < 0.05). MT1A gene methylation showed a trend of being associated with higher mRNA expression level in astrocytomas. Increased MT genes expression in grade IV astrocytomas as compared to I-III grade astrocytomas could be associated with malignant tumour behaviour and progression.

Topics: Astrocytoma; Brain Neoplasms; Disease Progression; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Metallothionein; Neoplasm Grading; Promoter Regions, Genetic; RNA, Messenger

Gliomas are the most common primary brain tumors in adults and a significant cause of cancer-related mortality. A 9-gene signature was identified as a novel prognostic model reflecting survival situation obviously in gliomas.. To identify an mRNA expression signature to improve outcome prediction for patients with different glioma grades.. We used whole-genome mRNA expression microarray data of 220 glioma samples of all grades from the Chinese Glioma Genome Atlas (CGGA) database (http://www.cgga.org.cn) as a discovery set and data from Rembrandt and GSE16011 for validation sets. Data from every single grade were analyzed by the Kaplan-Meier method with a two-sided log-rank test. Univariate Cox regression and linear risk score formula were applied to derive a gene signature with better prognostic performance. We found that patients who had high risk score according to the signature had poor overall survival compared with patients who had low risk score. Highly expressed genes in the high-risk group were analyzed by gene ontology (GO) and gene set variation analysis (GSVA). As a result, the reason for the divisibility of gliomas was likely due to cell life processes and adhesion.. This 9-gene-signature prediction model provided a more accurate predictor of prognosis that denoted patients with high risk score have poor outcome. Moreover, these risk models based on defined molecular profiles showed the considerable prospect in personalized cancer management.

Topics: Brain Neoplasms; Cell Cycle Proteins; DNA-Binding Proteins; Endosomal Sorting Complexes Required for Transport; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Variation; Genomic Library; Glioma; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Kaplan-Meier Estimate; Membrane Proteins; Metallothionein; Microarray Analysis; Microtubule-Associated Proteins; Nuclear Proteins; rab1 GTP-Binding Proteins; Repressor Proteins; RNA, Messenger; Survivin; TEA Domain Transcription Factors; Transcription Factors; Tubulin

Metallothionein 1E (MT1E) has been found to be highly expressed in motile cell lines. We investigated whether MT1E actually modulates the migration and invasion of human glioma cell lines and the types of factors that have an effect on MT1E. RNA differential display was performed using Genefishing™ technology in the human glioma cell lines U343MG-A, U87MG and U87MG-10'; the results were validated by RT-PCR and northern blot analysis, in order to detect possible genetic changes as the determining factors for migration ability in malignant glioma. MT1E was identified in U87MG, a highly motile cell line. The migration and invasion abilities of human glioma cell lines, and MT1E transfectants were investigated using simple scratch testing and Matrigel invasion assays. Morphological and cytoskeletal (actin, vimentin) changes were documented by light and confocal microscopy. The expression of MT1E in four glioma cell lines was assessed by RT-PCR and western blotting. In addition, the effects of MT1E on the activity of the NF-κB p50/p65 transcription factor, MMP-2 and -9 were examined by western blotting and zymography. The endogenous MT1E expression in the human glioma cell lines was statistically correlated with their migratory abilities and invasion. The U87-MT-AS cells became more round and had decreased stress fibers, compared with the U87MG cells. Endogenous MT1E expression in the four human glioma cell lines was directly correlated with migration. Two antisense MT1E-transfected cell lines showed decreased NF-κB p50 translocation into the nucleus, which led to decreased activity of MMP-9 in conditioned media. It may be postulated that MT1E can enhance the migration and invasion of human glioma cells by inducing MMP-9 inactivation via the upregulation of NF-κB p50.

Topics: Brain Neoplasms; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metallothionein; Neoplasm Invasiveness; NF-kappa B p50 Subunit; Transcriptional Activation; Transfection

Metallothioneins (MT) are common proteins in animal tissues. These proteins take part in the homeostasis of the ions of the metals which are necessary for the proper metabolism of the organism (zinc, copper), biosynthesis regulation and zincprotein activity (for example the activity of the zinc-dependant transcription factors) and they also take part in the detoxication of the tissue from toxic metals. Apart from these, they also protect the tissue from reactive oxygen species, radiation, electrophilic pharmacological agents used in the cancer therapy and the mutagens. The aim of this work was to obtain cellular sub-fractions of brain tumors and to separate these proteins by SDS-polyacrylamide gel electrophoresis and Western Blotting technique and to determine the level of metallothioneins and to determine the level of metallthioneins in the cellular sub-fraction. The experimental materials were the brain neoplastic tissues resected during neurosurgical procedures. The brain tumors were divided into two groups; astrocytoma G-2 and malignant gliomas (astrocytoma GM-4, glioblastoma multiforme). The cellular fractions of tumour tissues were obtained according to Clark and Nicklas and Chauveau et al. methods. The level of the metallothioneins was determined by the cadmium-hemoglobin affinity assay using the cadmium isotope (109Cd). By performing protein dissection on polyacrylamide gel (PAGE) and applying immunoidentifying technique we proved the presence of metallothioneins in all the cell sub-fractions. In GM-4 patients the total MT level increased by 12.06% whereas in the cytosol sub-fraction it increased by 17.02% in comparison with astrocytoma G-2 patients. In the mitochondrial sub-fraction the level increased by 49.09% while in the nuclear and microsomal sub-fractions the increase was by 22.38 and 8.24%, respectively.

Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Electrophoresis, Polyacrylamide Gel; Glioma; Humans; Metallothionein; Subcellular Fractions

Metallothioneins take part in the homeostasis of the ions of the metals which are necessary for the proper metabolism of the organism (zinc, copper), in biosynthesis regulation of the zinc-containing proteins and also in the detoxication of metals from the tissues. They also protect the tissue from the effects of free radicals, radiation, electrophilic pharmacological agents used in the cancer therapy and from mutagens. The experimental materials were brain astrocytomas, benign gliomas and malignant gliomas. The levels of the metallothionein were determined by cadmium-haemoglobin affinity assay using the cadmium isotope (109Cd). The values of zinc and copper were determined by means of atomic absorption spectrophotometry. In our studies, the level of metallothioneins in the group of malignant neoplasms was slightly higher than the level of these proteins in the group of benign neoplasms. The correlation coefficient of the studied parameters proved an interrelation between the levels of zinc and copper and the content of metallothioneins. In malignant neoplasms, the level of zinc showed a positive relationship with the metallothionein level, whereas the copper content showed an inverse relationship. There was a statistical difference, but no significant difference, in the levels of copper between malignant and benign groups.

Topics: Brain Neoplasms; Copper; Culture Techniques; Humans; Metallothionein; Spectrophotometry; Zinc

Metallothioneins take part in the homeostasis of the ions of the metals which are necessary for the proper metabolism of the organism (zinc, copper), biosynthesis regulation of the zinc containing proteins. They also take part in the detoxication of metals from the tissues. Besides,they protect the tissue from the effects of free radicals, radiation, electrophilic pharmacologic agents used in the cancer therapy and from mutagens. The experimental materials were brain astrocytomas, benign gliomas (astrocytoma G-2) and malignant gliomas (glioblastoma multiforme GM-4). The levels of the metallothionein were determined by cadmium-hemoglobin affinity assay using the cadmium isotope (109Cd). The value of zinc and copper were determined by means of atomic absorption spectrophotometry. In our studies, the level of metallothioneins in the group of malignant neoplasms was slightly higher than the level of these proteins in the group of benign neoplasms. There was a statistical difference, but there is no significant difference in the levels of copper between malignant and benign groups.

Topics: Astrocytoma; Brain Neoplasms; Copper; Culture Techniques; Female; Glioblastoma; Humans; Male; Metallothionein; Spectrophotometry, Atomic; Zinc

Malignant gliomas are largely resistant to current chemotherapeutic strategies often displaying a multidrug-resistant phenotype. Mechanisms involved in drug resistance are reduced cellular drug accumulation through membrane efflux pumps, drug detoxification as well as alterations in drug target specificity. In 27 primary and 17 secondary glioblastomas and their astrocytic precursor tumors, we studied the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), lung resistance-related protein (LRP), metallothionein, and topoisomerase II alpha. Glial tumor cells in all glioblastomas showed constant up-regulation of LRP, MRP, and topoisomerase II alpha. P-gp was found in 90% of the primary and 60% of the secondary glioblastomas. In precursor tumors, these drug resistance-related factors were expressed in varying proportions. Metallothionein, also found in normal and activated astrocytes, was retained in all neoplastic phenotypes. Furthermore, metallothionein, P-gp, LRP, and topoisomerase II alpha were strongly expressed by normal and neoplastic vessels which may confer to impaired penetration of therapeutic agents through the blood-brain and blood-tumor barrier. However, the expression profiles of drug resistance-related proteins neither differed between primary and secondary glioblastomas nor revealed any correlation to precursor or recurrent tumors. Nevertheless, inhibition of these factors may be promising approaches to the management of malignant gliomas.

Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Brain Neoplasms; Cell Membrane; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Glioblastoma; Humans; Immunoenzyme Techniques; Isoenzymes; Metallothionein; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Vault Ribonucleoprotein Particles

Intracranial ependymomas are the third most common primary brain tumor in children. A variety of chemotherapy protocols have been introduced for the treatment of ependymoma although overall these have not contributed to patients outcome. To our knowledge, data on the prognostic value of immunoexpression of the chemoresistance-related proteins (ChRPs) in ependymomas are absent. Seventy-six patients with intracranial ependymomas who received combined treatment were studied retrospectively. Tumor specimens were immunohistochemically examined with antibodies to metallothioneins (MT), glutathione S-transferase pi (GST pi) and P-glycoprotein (P-GP). The results demonstrated significant preponderance of expression of all the above-mentioned ChRPs for the low-grade tumors. The progression-free survival time was found to be significantly shorter for immunonegative tumors in both tumor grades. Multivariate analysis using a Cox hazard model revealed that recurrence-free survival time is significantly associated with tumor grade, and MT and P-GP expression. Risk of recurrence increased for the high-grade ependymomas (hazard ratio 2.85; P = 0.004), and decreased for the MT-positive tumors (hazard ratio -2.72; P = 0.005) and for the P-GP-positive tumors (hazard ratio -2.02; P = 0.02). The obtained results allow one to conclude that ChRPs expression is closely associated with low-grade ependymomas and immunohistochemical findings may be estimated as a predictor for local tumor progression.

Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Child; Drug Resistance, Neoplasm; Ependyma; Ependymoma; Female; Follow-Up Studies; Glutathione Transferase; Humans; Male; Metallothionein; Neoplasm Recurrence, Local; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome

To study the neurophysiological functions of metallothioneins (MTs), localization of MT-I and -II was examined immunohistochemically in a variety of brain lesions in dogs, including infarct, laminar cortical necrosis, hemorrhage, invasive growth of tumour, inflammatory lesions in granulomatous meningoencephalitis and distemper encephalitis. MT-I and -II were demonstrated in both nucleus and cytoplasm of hypertrophic astrocytes in most brain lesions examined regardless of the type, size, localization and duration of the lesions. In addition, MT expression was stronger in a population of hypertrophic astrocytes localizing inside of the surviving brain tissue rather than those localizing at the boundary between the surviving brain tissue and necrotic area, where severe inflammatory changes were developing. These results suggest that MT-I and -II may play roles not only in protection of neurons from metals and free radicals ubiquitous in the inflammatory lesions but also in repair of injured neural tissues.

Topics: Adenocarcinoma; Animals; Astrocytes; Brain Diseases; Brain Neoplasms; Cerebral Hemorrhage; Cerebral Infarction; Distemper; Dog Diseases; Dogs; Encephalitis, Viral; Female; Glial Fibrillary Acidic Protein; Hypertrophy; Inflammation; Male; Meningoencephalitis; Metallothionein; Necrosis; Neoplasm Invasiveness; Pituitary Neoplasms

Metallothioneins (MTs) are metal binding proteins overexpressed in various human neoplasms which are associated with resistance to cytotoxic drugs. A series of 156 archival human brain tumours were investigated immunohistochemically for expression of MTs; these included 10 low-grade gliomas, 44 high-grade gliomas, 98 meningeal tumours (19 classical, 30 atypical, 38 anaplastic meningiomas, and 11 haemangiopericytomas or papillary meningiomas), and 4 other tumours. Low-grade gliomas showed heterogeneous MT expression; 32 high-grade gliomas (72.7%) showed MT expression of more than 25% of tumour cells without statistically significant differences between first operations and recurrent tumours. In 2 glioblastomas, the presence of MT was confirmed by Western blotting. The extent of MT immunoexpression showed a statistically significant inverse relationship to the degree of p53 immunoreactivity. In meningiomas, a tendency to a higher percentage of MT-expressing cells was observed from classical over atypical to anaplastic meningiomas, but these differences were not statistically significant. In conclusion, MT expression is present in a significant portion of, especially malignant, brain tumours and might be involved in their poor response to antineoplastic drugs.

Topics: Adult; Aged; Blotting, Western; Brain Neoplasms; Child; Child, Preschool; Female; Glioma; Humans; Immunohistochemistry; Male; Meningioma; Metallothionein; Middle Aged; Neoplasm Staging; Tumor Suppressor Protein p53

Prostate carcinoma is the second leading cause of death from malignancy in men in the United States. Prostate cancer cells express type I insulin-like growth factor receptor (IGF-IR) and prostate cancer selectively metastazises to bone, which is an environment rich in insulin-like growth factors (IGFs), thereby supporting a paracrine action for cancer cell proliferation. We asked whether the IGF-IR is coupled to tumorigenicity and invasion of prostate cancer. When rat prostate adenocarcinoma cells (PA-III) were stably transfected with an antisense IGF-IR expression construct containing the ZnSO4-inducible metallothionein-1 transcriptional promoter, the transfectants expressed high levels of IGF-IR antisense RNA after induction with ZnSO4, which resulted in dramatically reduced levels of endogenous IGF-IR mRNA. A significant reduction in expression both of tissue-type plasminogen activator and of urokinase-type plasminogen activator occurred in PA-III cells accompanying inhibition of IGF-IR. Subcutaneous injection of either nontransfected PA-III or PA-III cells transfected with vector minus the IGF-IR insert into nude mice resulted in large tumors after 4 weeks. However, mice injected with IGF-IR antisense-transfected PA-III cells either developed tumors 90% smaller than controls or remained tumor-free after 60 days of observation. When control-transfected PA-III cells were inoculated over the abraded calvaria of nude mice, large tumors formed with invasion of tumor cells into the brain parenchyma. In contrast, IGF-IR antisense transfectants formed significantly smaller tumors with no infiltration into brain. These results indicate an important role for the IGF/IGF-IR pathway in metastasis and provide a basis for targeting IGF-IR as a potential treatment for prostate cancer.

Topics: Adenocarcinoma; Animals; Base Sequence; Brain Neoplasms; Cell Division; Cell Line; DNA Primers; Gene Expression; Male; Metallothionein; Mice; Mice, Nude; Molecular Sequence Data; Neoplasm Invasiveness; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Neoplasms; Rats; Receptor, IGF Type 1; Restriction Mapping; RNA, Antisense; Sulfates; Transcription, Genetic; Transfection; Transplantation, Heterologous; Zinc Compounds; Zinc Sulfate

Glioblastoma multiforme represents one of the most malignant forms of primary intracranial tumors, often intractable to multimodality of treatment including chemotherapy. The unsatisfactory results of chemotherapy are chiefly attributed to chemoresistance. Since various molecules that could confer drug resistance have been elucidated, screening of the amount of such molecules in the tumor cells could provide possibilities for predicting their chemoresistance beforehand and help select more effective drugs.. We present a 45-year-old woman with recurrent glioblastoma multiforme in the cerebellum and invading the brain stem, treated successfully by postoperative chemotherapy. In this patient, anticancer drugs were determined by measurements of mRNA expression of chemoresistance-related genes, such as O6-methylguanine-DNA methyltransferase (MGMT), mdr1, glutathione S-transferase (GST)-pi, and metallothionein (MT) in the resected tumor.. Northern blot analysis demonstrated the moderate mRNA level of MGMT, a major molecule causing ACNU (1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitroso ure a hydrochloride) resistance. On the other hand, expression levels of mdr1 which codes the P-glycoprotein responsible for multidrug resistance, and GST-pi, a detoxification enzyme, were low. Transcript of MT, another thiol containing molecule for cellular detoxification possibly associated with cisdiamminedichloroplatinum(II) (CDDP) resistance, was only faintly detectable. Postoperatively, the patient was treated initially with intravenous administration of ACNU and etoposide (VP16), resulting in a minor response of tumor regression. For maintenance therapy, we changed ACNU to CDDP according to the findings of the Northern blot analysis. Consequently, the residual tumor showed a marked response and almost disappeared after two courses of systemic chemotherapy with CDDP and VP16.. The successful tumor regression in this case suggests that Northern blot analysis on expression of these chemoresistance-related genes in tumor tissues could provide beneficial information for determination of optimal anticancer agents to improve the efficacy of chemotherapy.

Topics: Antineoplastic Agents; Blotting, Northern; Brain Neoplasms; Brain Stem; Cerebellar Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glioblastoma; Glutathione Transferase; Humans; Metallothionein; Methyltransferases; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; O(6)-Methylguanine-DNA Methyltransferase; RNA, Messenger; RNA, Neoplasm

Metallothionein (MT), a ubiquitous intracellular protein, confers resistance to the toxic effects of platinum compounds. Since a high-zinc diet has been shown to induce MT synthesis in extracerebral tissues but not in brain, we investigated whether it could provide an experimental basis for decreasing the hematotoxicity of carboplatin without impairing its activity against brain tumors. After 2 weeks on either a high-zinc diet or a control diet (zinc content, 180 vs 10 ppm), mice and rats received various doses of carboplatin or Hanks' balanced salt solution by i.p. injection. The hematotoxicity of carboplatin was evaluated with an assay of colony-forming units of granulocytes and mononuclear cells in mice. The high-zinc diet enabled a 50% increase in the carboplatin dose without increasing hematotoxicity. The antitumor activity was evaluated with an assay of the colony-forming efficiency of gliosarcoma cells from 9L brain tumors in rats. The high-zinc diet did not alter the efficacy of carboplatin against this brain tumor. Northern blot analysis confirmed that the high-zinc diet induced MT mRNA in the kidney but not in the brain of mice and rats; it also showed MT mRNA induction in bone marrow cells of mice but not in rat 9L brain tumors. These results suggest that increasing the dietary intake of zinc might increase the therapeutic index of carboplatin in the treatment of brain tumors.

Topics: Animals; Blotting, Northern; Brain; Brain Neoplasms; Carboplatin; Diet; Hematopoietic Stem Cells; Kidney; Metallothionein; Mice; Rats; RNA, Messenger; Tumor Stem Cell Assay; Zinc